2024.04.05
ROCKVILLE, MD, April 5, 2024 – I-Mab (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that management will present at the 23rd Annual Needham Virtual Healthcare Conference on April 11, 2024. 23rd Annual Needham Virtual Healthcare Conference […]
2024.04.03
ROCKVILLE, MD, April 2, 2024 – I-Mab (the “Company”) (NASDAQ: IMAB) a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that all conditions precedent to the divestiture transaction previously announced on February 7, 2024 (the “Transaction”) have been either satisfied […]
2024.03.14
The Company announced financial results for the full year ended December 31, 2023, and highlighted recent business updates.
2024.02.07
The agreement marks an important milestone to advance the Company’s intent to become a U.S.-based biotech.
2023.11.06
The Company will have presentations and one-to-one meetings during the upcoming two investor conferences.
2023.11.02
CD38 antibody felzartamab has been granted Breakthrough Therapy Designation by the U.S. FDA, following the Orphan Drug Designation received in May 2023.
2023.11.01
The Company will report preclinical data of givastomig and TJ-L14B, respectively, at the upcoming SITC 2023.
2023.10.16
The Company will present updated clinical data of givastomig at the upcoming ESMO Congress 2023.
2023.10.10
The Company announced multiple recent developments for TJ-L14B.
2023.09.05
I-Mab announced participation in investor conferences in September 2023.